T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes in which multiple genetic defects cooperate during pathogenesis resulting in uncontrolled cell growth. For T-ALL, a large variety of genetic rearrangements have been identified, including chromosomal translocations, deletions, amplifications, duplications and mutations. Translocations predominantly involve aberrant rearrangements of the T-cell receptor (TCR) loci during T-cell development through illegitimate V(D)J recombination. These recombination errors ultimately result in the activation of oncogenes. 1 One such important oncogene is LMO2. In the t(11;14) (p13;q11) and t(7;11)(q35;p13) translocations, the LMO2 gene is brought in close proximity of the TCRa/d or TCRb enhancers possibly boosting LMO2 expression. 1 Hammond et al. 2 demonstrated that deletion of a negative regulatory element (NRE) located just upstream the LMO2 locus also activates the LMO2 gene. This alternative mechanism for LMO2 activation also occurs in human cancer as we identified the recurrent interstitial deletion, del(11)(p12p13), in pediatric T-ALL in which loss of the NRE region is associated with LMO2 activation. 3 It was recently proposed that for most LMO2 translocations, LMO2 activation is presumably caused by the loss of the NRE region during the translocation event rather than the juxtaposition of LMO2 in the vicinity of the TCR enhancers. 4 
Figure 1
Multiplex ligation probe amplification (MLPA) analysis of the LMO2 gene in pediatric T-cell acute lymphoblastic leukemia (T-ALL). (a) Overview of the localization of the MLPA probes in the genomic locus surrounding the LMO2 gene at chromosomal band 11p13. (b) MLPA analysis of four del(11)(p12p13)-positive cases for the genomic loci described in (a). For each MLPA probe, the peak intensity, relative to the endogenous reference peak (LMO2 exon 6), is shown for each case. When two copies are present for each indicated genomic region, the relative peak intensities range between 0.9 and 1.1. Peak intensities between 0.4 and 0.6 indicate a one-copy loss for that specific region. (c) Similar MLPA analysis on different childhood T-ALL cases revealed an additional T-ALL case (no. 2845) with an LMO2 deletion, starting in between 500 and 1200 bp upstream of the LMO2 gene.
Letters to the Editor
The NRE region is a relatively small domain comprised by a region of approximately 3000 base pairs directly upstream of the transcription initiation site of LMO2.
2 Our initial screening for LMO2 translocations or cryptic LMO2 deletions using fluorescence in situ hybridization (FISH) on 138 childhood T-ALL cases 3 may have been unsuccessful to detect relatively small deletions upstream of LMO2, including this NRE region. For this reason, we developed a multiplex ligation probe amplification (MLPA) assay 5 with multiple probes located in or just flanking the NRE region to detect such smaller deletions upstream of LMO2 (Figure 1a ). Using some of our previously identified del(11)(p12p13)-positive cases 3 as positive controls, the MLPA assay confirmed the location of the telomeric breakpoints in these samples (Figure 1b) . Rescreening of our cohort revealed one additional T-ALL case (no. 2845) with an LMO2 deletion that had remained undetected in our previous FISH screening ( Figure 1c ). Oligo array-comparative genomic hybridization (CGH) analysis on patient DNA confirmed the presence of the deletion, del(11)(p13p13), which was about 400 kb in size and included the part of the NRE element and the centromeric genes CAPRIN1, NAT10 and ABTB2 (Figure 2a ). Copy number variations at this specific genomic locus have not been reported for the normal population. 6 In addition, FISH analysis using a bacterial artificial chromosome (BAC) clone situated just upstream of LMO2 (RP11-98C11) in combination with an LMO2 telomeric BAC clone (RP11-646J21) confirmed the loss of this genomic region ( Figure 2b ). This indicates that smaller del(11)(p13p13) deletions compared to the del(11)(p12p13) deletions as previously described 3 occur in pediatric T-ALL (Figure 2c) . Because of the differences in the deletion area among T-ALL cases, MLPA analysis could serve as a valuable additional tool to FISH screening for the proper identification of LMO2 rearranged T-ALL cases.
To study the effect of this deletion in case no. 2845 in relation to LMO2 expression, the LMO2 mRNA expression level for this case as measured using quantitative real-time RT-PCR (RQ-PCR) was compared to the expression levels of 66 LMO2 rearranged and non-rearranged T-ALL cases ( Figure 3 ). As LMO2 is normally highly expressed in early T-cell development and is repressed during later development stages, 7-9 we distinguished T-ALL cases with an immature immunophenotype (IM: Cytb À , mCD3 
TCRab þ or TCRgd þ ). 10 The leukemic cells from case no. 2845 had a mature immunophenotype and showed high LMO2 levels comparable to levels as observed in other LMO2 rearranged cases. 3 Pre-ab and mature T-ALL cases without LMO2 rearrangements significantly expressed lower LMO2 levels ( Figure 3) .
About half of the immature T-ALL cases without LMO2 rearrangements also displayed high LMO2 levels comparable to levels as observed in LMO2 rearranged cases. Although postulated as an oncogenic mechanism in the absence of cytogenetic rearrangements by Ferrando et al., 7 high LMO2 expression levels could also be attributed to a residual characteristic of early T-cell development 7-9 rather than reflecting an oncogenic hit. In support of this notion, 7 of 12 IM T-ALL cases with high LMO2 levels (above the median; Figure 3 ) are characterized by other recurrent abnormalities that are commonly mutually exclusive and may delineate specific subgroups in T-ALL. From these, five single cases had an MLL-MLLT4 translocation, a PICALM-MLLT10 translocation, an MYB-TRB@ translocation, a TAL2-TRB@ translocation or a TLX1 rearrangement, while two cases had a TLX3 rearrangement.
To further support that high LMO2 expression in these IM T-ALL cases is a reflection of early T-cell maturation arrest rather than an oncogene activation mechanism, we investigated whether LMO2 expression was driven from a single allele or both alleles. For this, we performed allele-specific LMO2 mRNA analysis 7 using a reverse transcription (RT)-PCR and sequencing approach on selected T-ALL cases including 27 TAL1 rearranged cases, 14 LMO2 rearranged cases, 1 MLLrearranged case and 25 cases lacking currently known molecular-cytogenetic abnormalities. These latter cases are denoted as 'unknown' cases. A total of 34 of these 67 samples were informative (heterozygous) at the DNA level for a single nucleotide polymorphism in the 3 0 -UTR region of LMO2 including 13 TAL1 rearranged, 9 LMO2 rearranged and 1 MLL rearranged case as well as 11 unknown cases (Table 1) . Abbreviation: T-ALL, T-cell acute lymphoblastic leukemia.
All LMO2 rearranged cases analyzed demonstrated monoallelic LMO2 activation (Figure 4 ; Table 1 ), indicating that cis-acting mechanisms (loss of the NRE and/or juxtaposition to the TCR enhancer) resulted in ectopic LMO2 expression of the rearranged allele with no or negligible expression of the remaining wild-type allele. A number of T-ALL cases without known LMO2 rearrangements also expressed LMO2 in a monoallelic manner. Although the LMO2 expression levels in these cases are relatively low, it would still be possible that they contain deletions, insertions or point mutations in the NRE region, which have remained undetected by FISH or MLPA analysis. Most TAL1 rearranged cases as well as about half of all LMO2/TAL1 nonrearranged cases with lower LMO2 levels compared to the LMO2 rearranged cases demonstrated biallelic LMO2 expression (Figure 4 ). Biallelic LMO2 expression was also observed for the three LMO2 wild-type cases with an immature phenotype (one MLL þ case and two unknown cases) that had the highest LMO2 expression levels comparable to LMO2 rearranged cases.
In conclusion, our study confirms that MLPA analysis for the detection of deletions upstream of LMO2 gene, which includes the NRE region, is a valuable tool to screen T-ALL patients for the del(11)(p12p13) mostly leading to ectopic LMO2 expression. Furthermore, biallelic activation of LMO2 in immature T-ALL cases may reflect their early T-cell development stage rather than it represents a true oncogenic mechanism. Mono-or biallelic LMO2 expression in pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients. LMO2 mRNA expression levels relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (%) for 34 selected pediatric T-ALL patients. Mono-or biallelic expression of the LMO2 gene is visualized as open or filled circles, respectively.
